Pfizer Inc.

PFE · NYSE · ·

Compare

$29.45+0.3%Nov 11 close

Figures through September 27, 2026, from the 10-Q filed November 3, 2026

1W: +0.2%
1M: +5.3%

Pfizer Inc. (PFE) stock — is it a good business? — InspectStocks

Pfizer Inc.

PFE · NYSE · ·

Compare

$29.45+0.3%Nov 11 close

Figures through September 27, 2026, from the 10-Q filed November 3, 2026

1W: +0.2%
1M: +5.3%

Just reported

Q3 2026 results

From Pfizer's results release of November 3, 2026; its quarterly report has since been filed.

Revenue
Actual
$16.58B
-0.4% y/y
+10% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0.56
-9.7% y/y
Guided
—
No guide given

Company outlook

Full year 2026

EPS, adjusted$2.95 – $3.05Raised +3.4%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

How it makes money

Sales of its medicines and vaccines95%
Royalties3%
Contract manufacturing and drug ingredients2%
Research and development services0%

Shares of revenue are estimates for year ended December 31, 2025, high confidence, not figures from a filing.

Competes with

What it sells6

Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.

Show 3 more

Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.

Who buys it4

Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.

What it stands on, and what could break it

What the business leans on

1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.

What could go wrong

1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.

Full financial statements →

About Pfizer Inc.

Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.

Head office: New York City, New York
Founded: 1849 (company founded, high confidence)
Employees: 75,000 (December 31, 2025, high confidence)
Listed on: NYSE
Financial year ends: December 31

Built from Pfizer Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported

Q3 2026 results

From Pfizer's results release of November 3, 2026; its quarterly report has since been filed.

Revenue
Actual
$16.58B
-0.4% y/y
+10% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0.56
-9.7% y/y
Guided
—
No guide given

Company outlook

Full year 2026

EPS, adjusted$2.95 – $3.05Raised +3.4%

Keep exploring

The themes Pfizer is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

How it makes money

Sales of its medicines and vaccines95%
Royalties3%
Contract manufacturing and drug ingredients2%
Research and development services0%

Shares of revenue are estimates for year ended December 31, 2025, high confidence, not figures from a filing.

Competes with

What it sells6

Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.

Show 3 more

Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.

Who buys it4

Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.

What it stands on, and what could break it

What the business leans on

1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.

What could go wrong

1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.

Full financial statements →

About Pfizer Inc.

Head office: New York City, New York
Founded: 1849 (company founded, high confidence)
Employees: 75,000 (December 31, 2025, high confidence)
Listed on: NYSE
Financial year ends: December 31

Pfizer Inc.

Pfizer Inc.

Q3 2026 results

Revenue

EPS, GAAP

Company outlook

How it makes money

Competes with

What it sells6

Who buys it4

What it stands on, and what could break it

What the business leans on

What could go wrong

About Pfizer Inc.

Q3 2026 results

Revenue

EPS, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells6

Who buys it4

What it stands on, and what could break it

What the business leans on

What could go wrong

About Pfizer Inc.

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Growth & cash — 4 of 5

Business trend

Share price and grade over time